NanoViricides, Inc. (NYSE American: NNVC) has announced receipt of National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency ACOREP, and noted that NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation upon regulatory approval.
According to the company, NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings. NanoViricides believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines.
This development is significant because the Bundibugyo ebolavirus lacks approved treatments or vaccines, and oral administration could greatly simplify treatment logistics in remote areas where cold chain and IV infrastructure are scarce. The trial's success could also validate the company's platform technology for other viral diseases.
For more details, the full press release is available at https://ibn.fm/MuxOe. Additional information about NanoViricides can be found on its website at https://www.nanoviricides.com.
The company emphasizes that NV-387 is a broad-spectrum antiviral drug candidate being developed for multiple indications, including respiratory syncytial virus (RSV), COVID-19, influenza, and mpox. However, as with all drug development, there are no guarantees of success in clinical trials or eventual regulatory approval.
